Schering-Plough stock down on Vytorin sales

Schering-Plough's stock took a dive this week after the news spread that sales of its troubled cholesterol drugs dropped significantly in November, after stablizing in October. Schering-Plough reported in its SEC filing this week that the number of prescriptions filled for Zetia were down almost 9 percent from October to November and Vytorin sales dropped 10 percent. According to IMS Health data quoted by Schering-Plough, overall cholesterol drug prescriptions filled fell by 6.7 percent in that same period, the Associated Press reports.

As you know, scrips for the troubled Vytorin have been dropping for some time. The decline slowed in June and seemed to stabilize in October. Analyst Seamus Fernandez of Leerink Swan LLC tells the AP that investors are overreacting: "To take monthly prescription numbers and panic about them doesn't make a whole lot of sense," he said. There are several likely explanations for the drop in cholesterol drug sales from October to November include the recession, higher drug co-pays, fewer "selling days" in November because of the Thanksgiving holiday and a decrease in visits by pharma reps to physicians, Fernandez explained.

Meanwhile, Merck's stock remained virtually unaffected, rising 62 cents to end at $27.74.

- get the back story on Vytorin and Zetia
- read the AP article for more
- see what Pharmalot had to say

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.